{"id":4142,"date":"2025-07-17T12:11:19","date_gmt":"2025-07-17T09:11:19","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4142"},"modified":"2025-11-03T20:21:36","modified_gmt":"2025-11-03T17:21:36","slug":"insmed-ins1201-gene-therapy-phase-1-clinical-trial-nct06817382","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/insmed-ins1201-gene-therapy-phase-1-clinical-trial-nct06817382\/","title":{"rendered":"D\u00e9but de l&#039;essai clinique de phase 1 de la th\u00e9rapie g\u00e9nique INS1201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Insmed a annonc\u00e9 sur la page publi\u00e9e sur ClinicalTrials.gov avec l&#039;ID NCT06817382 que les essais de phase 1 de la th\u00e9rapie g\u00e9nique INS1201 d\u00e9velopp\u00e9e pour la dystrophie musculaire de Duchenne seront lanc\u00e9s.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table des mati\u00e8res<\/h2><nav><ul><li><a href=\"#bbm-d-101-gene-therapy-phase-1-2-clinical-trial\">Essai clinique de phase 1 sur la th\u00e9rapie g\u00e9nique INS1201<\/a><\/li><li><a href=\"#what-is-insmed-ins-1201-gene-therapy\">Qu&#039;est-ce que la th\u00e9rapie g\u00e9nique Insmed INS1201 ?<\/a><\/li><li><a href=\"#bbm-d-101-clinical-trial-nct-07058662\">Essai clinique INS1201 \u2013 NCT06817382<\/a><\/li><li><a href=\"#bbm-d-101-phase-1-2-participation-criteria\">Crit\u00e8res de participation \u00e0 la phase 1 de l&#039;INS1201<\/a><\/li><li><a href=\"#how-can-i-contact-with-belief-bio-med\">Comment puis-je contacter Insmed ?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-gene-therapy-phase-1-2-clinical-trial\">Essai clinique de phase 1 sur la th\u00e9rapie g\u00e9nique INS1201<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019objectif principal de cette \u00e9tude est d\u2019\u00e9valuer l\u2019innocuit\u00e9 et la tol\u00e9rance d\u2019une dose unique d\u2019INS1201 par administration IT chez des participants masculins ambulatoires atteints de DMD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-insmed-ins-1201-gene-therapy\">Qu&#039;est-ce que la th\u00e9rapie g\u00e9nique Insmed INS1201 ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;INS1201 cible directement le syst\u00e8me nerveux central et est administr\u00e9 par voie intrath\u00e9cale, contrairement au Elevidys, qui n\u00e9cessite une injection intraveineuse syst\u00e9mique. Les probl\u00e8mes de s\u00e9curit\u00e9 et d&#039;efficacit\u00e9 des traitements g\u00e9niques syst\u00e9miques devraient \u00eatre r\u00e9solus par cette strat\u00e9gie d&#039;administration cibl\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;administration intrath\u00e9cale r\u00e9duit consid\u00e9rablement la dose n\u00e9cessaire de dix \u00e0 cinquante fois, ce qui \u00e9vite la toxicit\u00e9 syst\u00e9mique et les effets hors cible en concentrant le m\u00e9dicament l\u00e0 o\u00f9 il est n\u00e9cessaire. Malgr\u00e9 les obstacles tels que les l\u00e9sions de la moelle \u00e9pini\u00e8re, les l\u00e9sions nerveuses et le risque d&#039;infections, cela pourrait offrir aux patients une option plus s\u00fbre et peut-\u00eatre plus efficace, en particulier \u00e0 la lumi\u00e8re des probl\u00e8mes de s\u00e9curit\u00e9 associ\u00e9s aux fortes doses de vecteur viral utilis\u00e9es dans la th\u00e9rapie intraveineuse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-clinical-trial-nct-07058662\">Essai clinique INS1201 \u2013 NCT06817382<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u00e9but de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2025-05-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement du primaire (estim\u00e9)<\/strong>: 2028-01-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ach\u00e8vement de l&#039;\u00e9tude (estim\u00e9)<\/strong>: 2028-03-31<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nombre de participants (estim\u00e9)<\/strong>: 12 (Homme)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Emplacements<\/strong>: \u00c9tats-Unis<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c2ges admissibles aux \u00e9tudes<\/strong>: 2 ans \u00e0 4 ans (enfant)<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bbm-d-101-phase-1-2-participation-criteria\">Crit\u00e8res de participation \u00e0 la phase 1 de l&#039;INS1201<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Les personnes doivent remplir les conditions d&#039;inclusion pour \u00eatre admissibles. Si une personne souffre d&#039;une autre maladie ou suit un traitement susceptible de l&#039;emp\u00eacher de b\u00e9n\u00e9ficier d&#039;une th\u00e9rapie g\u00e9nique, elle pourrait ne pas \u00eatre admissible \u00e0 participer. L&#039;ensemble des crit\u00e8res d&#039;inclusion et d&#039;exclusion est disponible en cliquant sur ce lien. <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06817382\" target=\"_blank\" rel=\"noreferrer noopener\">NCT06817382<\/a> \u2013.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"how-can-i-contact-with-belief-bio-med\">Comment puis-je contacter Insmed ?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nom<\/strong>: Informations m\u00e9dicales Insmed<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Num\u00e9ro de t\u00e9l\u00e9phone<\/strong>: 18444467633<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>E-mail<\/strong>: medicalinformation@insmed.com<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Insmed was announced on the page published on ClinicalTrials.gov with the ID NCT06817382 that the phase 1 trials of INS1201 gene therapy developed for Duchenne Muscular Dystrophy will be initiated. INS1201 Gene Therapy Phase 1 Clinical Trial The primary objective of this study is to evaluate the safety and tolerability of a single dose of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4148,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[137,61,173,174,172],"class_list":["post-4142","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-clinical-trial","tag-gene-therapy","tag-ins1201","tag-ins1201-gene-therapy","tag-insmed"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=4142"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/4142\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/4148"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=4142"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=4142"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=4142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}